Evidence map›Paper›PMID 41869302›Full record

ReviewFrontiers in immunology2026

Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.

Phoebe Crammond, Priyanka Hastak, Anthony Delaney, Sarah C Sasson

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Frontiers in immunology · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Phoebe CrammondImmunovirology and Pathogenesis Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Priyanka HastakImmunovirology and Pathogenesis Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Anthony DelaneyIntensive Care Unit, Royal North Shore Hospital, Sydney, NSW, Australia.
Sarah C SassonImmunovirology and Pathogenesis Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptor 4 (TLR4) is a pattern recognition receptor that binds to pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs). Binding of exogenous or endogenous ligands activates the TLR4 pathway and induces the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β and type 1 interferons including IFN-α and IFN-β. TLR4 plays a vital role in host defense against Gram-negative bacterial infections by recognizing lipopolysaccharides (LPS) and inducing inflammatory mediators to clear infection. However, there is emerging evidence that excessive TLR4 activation may be pathogenic in human diseases affecting the central nervous system, cardiovascular, respiratory and metabolic systems, thereby promoting inflammation and autoimmunity. In some diseases, the is conflicting evidence regarding pathogenic versus protective roles. Several TLR4 targeted therapeutics have been developed and studied in animal models, however many of these therapeutics including Eritoran and TAK-242 did not prove to be effective in clinical trials. Overall, TLR4 exhibits context-dependent protective and pathogenic roles across infectious and non-infectious diseases, reflecting the complexity of its signaling in human health and disease.

Indexed as

Toll-Like Receptor 4AnimalsHumansInflammationInnate Immunity RecognitionMolecular Targeted TherapySignal TransductionToll-Like Receptor AgonistsTLR4 protein, humanToll-Like Receptor 4Toll-Like Receptor Agonistsdamage associated molecular patterns (DAMPs)immunomodulating therapeuticsinnate immunitypathogen associated molecular patterns (MAMPs/PAMPs)TLR4TLR4 agonistsTLR4 antagoniststoll-like receptor 4

Identifiers

PMID41869302
PMCPMC12999816

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.